In 2017, six-year-old Tian Tian was diagnosed with Burkitt lymphoma. Despite undergoing several rounds of high-dose chemotherapy as the first line of treatment, he did not reach complete remission. He then received second-line chemotherapy, but the tumor continued to grow.

To further address his condition, Tian Tian was treated at Beijing GoBroad Boren Hospital. After a thorough evaluation, Professor Yonghong ZHANG created a personalized treatment plan for him. Due to the tumor's persistent progression, Tian Tian had three biopsies and underwent sequential CAR-T cell therapy targeting CD19, CD22, and CD20. Ultimately, he achieved complete remission, which he has maintained to this day. Now as middle school student, he leads a normal life, studying and enjoying time with friends.

Tian Tian is recognized as the first patient i with refractory/relapsed Burkitt lymphoma (R/R BL) to attain complete remission through the sequential infusion of CD19/CD20/CD22 CAR-T cells. This groundbreaking therapy offers a new treatment option for refractory relapsed Burkitt lymphoma.